PMID- 26883680
OWN - NLM
STAT- MEDLINE
DCOM- 20170829
LR  - 20180206
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
VI  - 177
DP  - 2017 Apr
TI  - Natural killer cell adoptive immunotherapy: Coming of age.
PG  - 3-11
LID - S1521-6616(16)30019-5 [pii]
LID - 10.1016/j.clim.2016.02.003 [doi]
AB  - Cell therapy is a promising alternative to harsh chemotherapy and radiation 
      therapy for cancer. Natural killer (NK) cells in particular have great potential 
      for direct use in adoptive immunotherapy (AI) for cancer and to improve the 
      graft-vs-leukemia (GVL) effect of hematopoietic stem cell transplants (HSCTs). NK 
      cell number and function are associated with a strong GVL effect without inducing 
      graft-versus-host disease in most settings. Clinical trials demonstrating the 
      therapeutic role of NK cells in HSCT recipients or testing the safety and 
      efficacy of AI with NK cells have been primarily directed at treating acute 
      myeloid leukemia, although investigators have used NK cells for treatment of 
      other hematological diseases, sarcomas, carcinomas, and brain tumors. Major 
      challenges must be overcome in making NK cell-based therapy cost-effective, the 
      most important being the need to collect or generate an adequate number of 
      effector cells. In this review, we discuss protocols for isolation, expansion, 
      and in vitro propagation of large quantities of functional NK cells that meet the 
      criteria for clinical applications. Among the methods described are the use of 
      bioreactors for scaling up production and expansion of NK cells in the presence 
      of interleukins and feeder cells. We also discuss novel methodologies that 
      optimize the generation of clinical grade NK-cell products for AI.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Baggio, Leticia
AU  - Baggio L
AD  - Universidade Federal do Rio Grande do Sul, Av. Paulo Gama, Porto Alegre, RS 
      91501-170, Brazil; Centro de Tecnologia e Terapia Celular, Hospital de Clinicas 
      de Porto Alegre, R. Ramiro Barcelos, 2350, Porto Alegre, RS 90035-903, Brazil.
FAU - Laureano, Alvaro Macedo
AU  - Laureano AM
AD  - Universidade Federal do Rio Grande do Sul, Av. Paulo Gama, Porto Alegre, RS 
      91501-170, Brazil; Centro de Tecnologia e Terapia Celular, Hospital de Clinicas 
      de Porto Alegre, R. Ramiro Barcelos, 2350, Porto Alegre, RS 90035-903, Brazil.
FAU - Silla, Lucia Mariano da Rocha
AU  - Silla LMDR
AD  - Universidade Federal do Rio Grande do Sul, Av. Paulo Gama, Porto Alegre, RS 
      91501-170, Brazil; Centro de Tecnologia e Terapia Celular, Hospital de Clinicas 
      de Porto Alegre, R. Ramiro Barcelos, 2350, Porto Alegre, RS 90035-903, Brazil.
FAU - Lee, Dean Anthony
AU  - Lee DA
AD  - Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 
      Holcombe Boulevard, Houston, TX 77030, United States; Immunology Program, The 
      University of Texas Graduate School of Biomedical Sciences, 6767 Bertner Avenue, 
      Houston, TX 77030, United States. Electronic address: dalee@mdanderson.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160214
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
SB  - IM
MH  - Animals
MH  - Cell Transplantation
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Killer Cells, Natural/immunology/*transplantation
MH  - Lymphocyte Subsets
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Adoptive immunotherapy
OT  - Ex vivo expansion
OT  - Graft versus leukemia
OT  - Graft-versus-host disease
OT  - Hematopoietic stem cell transplant
OT  - Natural killer cells
EDAT- 2016/02/18 06:00
MHDA- 2017/08/30 06:00
CRDT- 2016/02/18 06:00
PHST- 2015/08/04 00:00 [received]
PHST- 2016/02/06 00:00 [revised]
PHST- 2016/02/09 00:00 [accepted]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2017/08/30 06:00 [medline]
PHST- 2016/02/18 06:00 [entrez]
AID - S1521-6616(16)30019-5 [pii]
AID - 10.1016/j.clim.2016.02.003 [doi]
PST - ppublish
SO  - Clin Immunol. 2017 Apr;177:3-11. doi: 10.1016/j.clim.2016.02.003. Epub 2016 Feb 
      14.